GRB14

Across TCGA pan-cancer cohorts, GRB14 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GRB14 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GRB14 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GRB14 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where GRB14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	IV	0.927	0.566	.019	6	view →
PDAC	DFS	Median	II,III,IV	0.612	0.280	.009	4	view →
LUAD	OS	Median	All	1.000	0.898	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GRB14–HNSC (DFS)

Open the HNSC breakdown →